Antagonistic mAbs specific for programmed cell death protein 1 (PD-1) and its ligand, programmed cell death 1 ligand 1 (PD-L1), have shown efficacy and have been approved by the FDA for use in a variety of cancer types (4). This evidence concerns the gene CD274 and cancer.